Home
IMMP
IMMP News

Latest Immutep Limited (IMMP) News on January 19, 2025

Immutep Limited (ASX:IMM) is largely controlled by institutional shareholders who own 51% of the company

Simply Wall St.

4 days ago

Immutep Limited (ASX:IMM) is largely controlled by institutional shareholders who own 51% of the company

Patient Enrolment Completed for INSIGHT-003

GlobeNewswire

13 days ago

Patient Enrolment Completed for INSIGHT-003

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

GlobeNewswire

a month ago

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II

GlobeNewswire

a month ago

Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II

Immutep announces results from Cohort B of TACTI-003 trial

TipRanks

a month ago

Immutep announces results from Cohort B of TACTI-003 trial

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

GlobeNewswire

a month ago

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

Immutep Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

GlobeNewswire

a month ago

Immutep Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

Exclusive: Prima, Mexico-based manufacturing and supply chain integrator, reveals it has raised $42.5 million

Fortune

a month ago

Exclusive: Prima, Mexico-based manufacturing and supply chain integrator, reveals it has raised $42.5 million

MT Newswires

2 months ago

Sector Update: Health Care Stocks Lower Thursday Afternoon

MT Newswires

2 months ago

Immutep Shares Rally Following Positive Phase 1 Trial Data of Efti Combination Therapy in Non-Small Cell Lung Cancer

Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

GlobeNewswire

2 months ago

Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual Meeting

GlobeNewswire

2 months ago

Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual Meeting

Immutep (ASX:IMM) shareholders have endured a 51% loss from investing in the stock three years ago

Simply Wall St.

2 months ago

Immutep (ASX:IMM) shareholders have endured a 51% loss from investing in the stock three years ago

Immutep Quarterly Activities Report Q1 FY25

GlobeNewswire

3 months ago

Immutep Quarterly Activities Report Q1 FY25

Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS <1) Head and Neck Cancer at ESMO Immuno-Oncology 2024

GlobeNewswire

3 months ago

Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS <1) Head and Neck Cancer at ESMO Immuno-Oncology 2024

MT Newswires

3 months ago

Immutep Completes Recruitment for Early-Stage Trial of IMP761, Advances to Dose Escalation

Immutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of Trial

GlobeNewswire

3 months ago

Immutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of Trial

Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit

GlobeNewswire

3 months ago

Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit

Immutep concludes participant enrolment in Phase II breast cancer trial

Clinical Trials Arena

4 months ago

Immutep concludes participant enrolment in Phase II breast cancer trial

Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer

GlobeNewswire

4 months ago

Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer

MT Newswires

4 months ago

Immutep Receives $2.5 Million R&D Tax Incentive From French Government

Immutep Receives A$3.6 million R&D Tax Incentive from French Government

GlobeNewswire

4 months ago

Immutep Receives A$3.6 million R&D Tax Incentive from French Government

New Data to be Presented from EFTISARC-NEO Phase II Evaluating Novel Triple Combination including Immutep’s Efti in Soft Tissue Sarcoma

GlobeNewswire

4 months ago

New Data to be Presented from EFTISARC-NEO Phase II Evaluating Novel Triple Combination including Immutep’s Efti in Soft Tissue Sarcoma

Immutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer

GlobeNewswire

4 months ago

Immutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer

Immutep Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress 2024

GlobeNewswire

5 months ago

Immutep Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress 2024

Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody

GlobeNewswire

5 months ago

Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody

Both retail investors who control a good portion of Immutep Limited (ASX:IMM) along with institutions must be dismayed after last week's 10% decrease

Simply Wall St.

5 months ago

Both retail investors who control a good portion of Immutep Limited (ASX:IMM) along with institutions must be dismayed after last week's 10% decrease

Immutep to Participate in Upcoming Investor Conferences

GlobeNewswire

5 months ago

Immutep to Participate in Upcoming Investor Conferences

Immutep Quarterly Activities Report Q4 FY24

GlobeNewswire

6 months ago

Immutep Quarterly Activities Report Q4 FY24

Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer

GlobeNewswire

6 months ago

Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer

MT Newswires

6 months ago

Immutep Receives Dutch Regulatory Approval to Begin Human Testing of Potential Autoimmune Treatment

Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases

GlobeNewswire

6 months ago

Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases

Immutep (IMMP) Up as Combo Therapy Meets Carcinoma Study Goals

Zacks

6 months ago

Immutep (IMMP) Up as Combo Therapy Meets Carcinoma Study Goals

MT Newswires

6 months ago

Top Midday Gainers

MT Newswires

6 months ago

Sector Update: Health Care

MT Newswires

6 months ago

Immutep Achieves 'Positive' Results From Cohort B of Phase 2B Cancer Trial; Shares Rise Pre-Bell

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression

GlobeNewswire

6 months ago

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression

Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results

GlobeNewswire

7 months ago

Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results

Prima BioMed (IMMP) Loses -34.84% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks

7 months ago

Prima BioMed (IMMP) Loses -34.84% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

MT Newswires

7 months ago

Immutep Gets Exclusive Rights to Develop, Commercialize New Anti-LAG-3 Small Molecules

Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer

GlobeNewswire

7 months ago

Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer

Lotto 6/49 - $64 million up for grabs in the next draw!

CNW Group

7 months ago

Lotto 6/49 - $64 million up for grabs in the next draw!

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Simply Wall St.

7 months ago

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Seoul says it will resume loudspeaker propaganda against North

AFP

7 months ago

Seoul says it will resume loudspeaker propaganda against North

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

Simply Wall St.

7 months ago

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Simply Wall St.

7 months ago

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Barrons.com

7 months ago

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

Simply Wall St.

7 months ago

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

Simply Wall St.

7 months ago

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

MT Newswires

7 months ago

Immutep Completes Stock Offering

Immutep successfully completes institutional placement and institutional component of entitlement offer

GlobeNewswire

7 months ago

Immutep successfully completes institutional placement and institutional component of entitlement offer

MT Newswires

8 months ago

Immutep, Merck Collaborate on Trial for Lung Cancer Therapy

Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial

GlobeNewswire

8 months ago

Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial

Immutep's (ASX:IMM) investors will be pleased with their notable 73% return over the last five years

Simply Wall St.

8 months ago

Immutep's (ASX:IMM) investors will be pleased with their notable 73% return over the last five years

MT Newswires

8 months ago

Immutep Says Safety Lead-in Phase of Breast Cancer Study Yields 'Encouraging' Data

Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024

GlobeNewswire

8 months ago

Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024

Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

GlobeNewswire

9 months ago

Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

Immutep Quarterly Activities Report Q3 FY24

GlobeNewswire

9 months ago

Immutep Quarterly Activities Report Q3 FY24

MT Newswires

9 months ago

Immutep Shows Positive Data in Trial to Treat Squamous Cell Cancers in Head, Neck

Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday?

Benzinga

9 months ago

Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday?

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

GlobeNewswire

9 months ago

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

GlobeNewswire

9 months ago

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

GlobeNewswire

9 months ago

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Immutep Limited (ASX:IMM): Is Breakeven Near?

Simply Wall St.

10 months ago

Immutep Limited (ASX:IMM): Is Breakeven Near?

11 Best ASX Stocks To Buy Now

Insider Monkey

10 months ago

11 Best ASX Stocks To Buy Now

Immutep Announces First Clinical Data from 90mg Dosing of Efti

GlobeNewswire

10 months ago

Immutep Announces First Clinical Data from 90mg Dosing of Efti

Individual investors account for 60% of Immutep Limited's (ASX:IMM) ownership, while institutions account for 29%

Simply Wall St.

a year ago

Individual investors account for 60% of Immutep Limited's (ASX:IMM) ownership, while institutions account for 29%

10 Best Australian Stocks To Buy

Insider Monkey

a year ago

10 Best Australian Stocks To Buy

Is There Any Hope for Cassava Sciences Stock?

Motley Fool

a year ago

Is There Any Hope for Cassava Sciences Stock?

Immutep Quarterly Activities Report Q2 FY24

GlobeNewswire

a year ago

Immutep Quarterly Activities Report Q2 FY24

The First of Long Island Corporation (NASDAQ:FLIC) Q4 2023 Earnings Call Transcript

Insider Monkey

a year ago

The First of Long Island Corporation (NASDAQ:FLIC) Q4 2023 Earnings Call Transcript

Those who invested in Northwest Pipe (NASDAQ:NWPX) five years ago are up 29%

Simply Wall St.

a year ago

Those who invested in Northwest Pipe (NASDAQ:NWPX) five years ago are up 29%

Chuck Royce Reduces Stake in NVE Corp

GuruFocus.com

a year ago

Chuck Royce Reduces Stake in NVE Corp

Renovaro Biosciences Announces Results of Special Meeting of Shareholders

GlobeNewswire

a year ago

Renovaro Biosciences Announces Results of Special Meeting of Shareholders

Ocular Therapeutix™ Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal Clinical Trial of AXPAXLI™ in Wet AMD

GlobeNewswire

a year ago

Ocular Therapeutix™ Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal Clinical Trial of AXPAXLI™ in Wet AMD

Argus Research

a year ago

Daily – Vickers Top Buyers & Sellers for 01/25/2024

Farmers National Banc Corp. Reports Year-End Growth Amidst Economic Challenges

GuruFocus.com

a year ago

Farmers National Banc Corp. Reports Year-End Growth Amidst Economic Challenges

McEwen (MUX) Loses -13.83% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks

a year ago

McEwen (MUX) Loses -13.83% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Petco (WOOF) Unveils Pet Insurance Offering With Nationwide

Zacks

a year ago

Petco (WOOF) Unveils Pet Insurance Offering With Nationwide

Exploring Analyst Estimates for Alerus (ALRS) Q4 Earnings, Beyond Revenue and EPS

Zacks

a year ago

Exploring Analyst Estimates for Alerus (ALRS) Q4 Earnings, Beyond Revenue and EPS

Associated Press Finance

a year ago

Greene County: Fiscal Q2 Earnings Snapshot

Greene County Bancorp, Inc. Reports Net Income of $12.2 million for the Six Months Ended December 31, 2023, and Celebrates the Bank of Greene County’s 135th Anniversary

GlobeNewswire

a year ago

Greene County Bancorp, Inc. Reports Net Income of $12.2 million for the Six Months Ended December 31, 2023, and Celebrates the Bank of Greene County’s 135th Anniversary

Nikola (NKLA) Stock Drops Despite Market Gains: Important Facts to Note

Zacks

a year ago

Nikola (NKLA) Stock Drops Despite Market Gains: Important Facts to Note

SmartFinancial Announces Results for the Fourth Quarter 2023

GlobeNewswire

a year ago

SmartFinancial Announces Results for the Fourth Quarter 2023

SEC Probes B. Riley Deals With Client Tied to Failed Fund

Bloomberg

a year ago

SEC Probes B. Riley Deals With Client Tied to Failed Fund

Amarin Chairman & CEO Issue Letter to Shareholders

GlobeNewswire

a year ago

Amarin Chairman & CEO Issue Letter to Shareholders

At US$9.40, Is It Time To Put Gambling.com Group Limited (NASDAQ:GAMB) On Your Watch List?

Simply Wall St.

a year ago

At US$9.40, Is It Time To Put Gambling.com Group Limited (NASDAQ:GAMB) On Your Watch List?

Dividend Challengers List Ranked By Yield: Top 30

Insider Monkey

a year ago

Dividend Challengers List Ranked By Yield: Top 30

Alector Announces Closing of Public Offering

GlobeNewswire

a year ago

Alector Announces Closing of Public Offering

Business Wire

a year ago

Western Asset High Income Fund II Inc. Authorizes Rights Offering

Q1’s Rising Stars: 3 Lithium Stocks for Your Must-Watch List

InvestorPlace

a year ago

Q1’s Rising Stars: 3 Lithium Stocks for Your Must-Watch List

Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility

GlobeNewswire

a year ago

Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility

Piedmont Lithium Sells Portion of Atlantic Shares to Assore

Business Wire

a year ago

Piedmont Lithium Sells Portion of Atlantic Shares to Assore

Are Investors Undervaluing Edgewell Personal Care (EPC) Right Now?

Zacks

a year ago

Are Investors Undervaluing Edgewell Personal Care (EPC) Right Now?

Unity Bancorp Reports Quarterly Earnings of $9.8 Million and Full Year Earnings of $39.7 Million

GlobeNewswire

a year ago

Unity Bancorp Reports Quarterly Earnings of $9.8 Million and Full Year Earnings of $39.7 Million

Gambling.com Group to Participate at 26th Annual Needham Growth Conference on January 18

Business Wire

a year ago

Gambling.com Group to Participate at 26th Annual Needham Growth Conference on January 18

Unisys Announces Participation in Upcoming Investor Conferences

PR Newswire

a year ago

Unisys Announces Participation in Upcoming Investor Conferences

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

GlobeNewswire

a year ago

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

Bridgewater Bancshares, Inc. to Announce Fourth Quarter 2023 Financial Results and Host Earnings Conference Call

Business Wire

a year ago

Bridgewater Bancshares, Inc. to Announce Fourth Quarter 2023 Financial Results and Host Earnings Conference Call

Strength Seen in Tree.com (TREE): Can Its 22.1% Jump Turn into More Strength?

Zacks

a year ago

Strength Seen in Tree.com (TREE): Can Its 22.1% Jump Turn into More Strength?

Share on Social Networks: